Protease inhibitor therapy and fetal growth potential in HIV-positive women

American Journal of Perinatology

Volumn 25, Issue 6, 2008, Pages 335-339

  Iqbal, Sara ^a   Kriebs, Jan ^a   Harman, Christopher ^a   Gungor, Sadettin ^a   Alger, Lindsay ^a   Turan, Ozhan ^a   Kopelman, Jerome ^a   Malinow, Andrew ^a   Baschat, Ahmet A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Fetal growth restriction; HIV; Pregnancy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; EMTRICITABINE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; TENOFOVIR; ZIDOVUDINE;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BIRTH WEIGHT; BODY HEIGHT; CD4 LYMPHOCYTE COUNT; CHI SQUARE TEST; CIGARETTE SMOKING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG UTILIZATION; FEMALE; FETUS GROWTH; GESTATIONAL AGE; GROWTH CURVE; GROWTH POTENTIAL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INTRAUTERINE GROWTH RETARDATION; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MATERNAL AGE; MULTIPLE REGRESSION; NEWBORN; PARITY; PREMATURE LABOR; PRENATAL CARE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; SEX DIFFERENCE; SUBSTANCE ABUSE; VIRUS LOAD; WEIGHT GAIN;

ADULT; FEMALE; FETAL GROWTH RETARDATION; HIV SEROPOSITIVITY; HUMANS; LOGISTIC MODELS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVALENCE; PROTEASE INHIBITORS; SMOKING;

EID: 52249117650     PISSN: 07351631     EISSN: 10988785     Source Type: Journal    
DOI: 10.1055/s-2008-1078757     Document Type: Article

References (16)

1. Centers for Disease Control and Prevention. Cases of HIV infection and AIDS in the United States and Dependent Areas, 2005 HIV/AIDS Surveillance Report, Volume 17, Revised Edition, June 2007. http://www.cdc. gov/hiv/topics/surveillance/resources/slides/pediatric/index.htm http://www.cdc.gov/hiv/topics/surveillance/resources/reports/ 2005report/table4.htm
2. Tuomala RE, Watts DH, LI D. Improved obstetric outcomes and few maternal toxicities are associated with ART, including HAART during pregnancy. J Acquir Immune Defic Syndr 2005;38:449-460
3. Fiscus SA, Adimora AA, Funk ML, et al. Trends in interventions to reduce perinatal human immunodeficiency virus type 1 transmission in North Carolina. Pediatr Infect Dis J 2002;21:664-668
4. Cotter AM, Garcia AG, Duthly ML, Luke B, O'Sullivan MJ. Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or still-birth? J Infect Dis 2006;193:1195-1201
5. Thorne C, Rudin C, Newell M, et al. The European Collaborative Study and The Swiss Mother+Child HIV Cohort study. Combination antiretroviral therapy and duration of pregnancy. AIDS 2000;14:2913-2920
6. Hankin C, Thorne C, Peckham C, Newell M. Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women. J Acquir Immune Defic Syndr 2003;32:380-387
7. Tuomala RE, Shapiro DE, Mofenson LM, et al. Antiretroviral therapy during pregnancy and the risk of an adverse outcome. N Engl J Med 2002;346:1863-1870
8. Morris AB,Dobles AR,Cu-Uvin S, et al. Protease inhibitor use in 233 pregnancies. J Acquir Immune Defic Syndr 2005;40: 30-33
9. Szyld EG, Warley EM, Freimanis L, et al. Maternal antiretroviral drugs during pregnancy and infant low birth weight and preterm birth. AIDS 2006;20:2345-2353
10. Gardosi J. Customized fetal growth standards: rationale and clinical application. Semin Perinatol 2004;28:33-40
11. Bukowski R, Burgett AD, Geui A, Saade GR, Hankins GD. Impairment of fetal growth potential and neonatal encephalopathy. Am J Obstet Gynecol 2003;188:1011-1015
12. Covington DL, Conner SD, Doi PA, Swinson J, Daniels EM. Risk of birth defects associated with nelfinavir exposure during pregnancy. Obstet Gynecol 2004;103:1181-1189
13. Beckerman K, Watts H, Covington D, et al. Assessing the risk of birth defects and other poor pregnancy outcomes associated with antiretroviral exposure during pregnancy. Poster presentation at the 16th International AIDS conference, Toronto, Canada, August 2006. Available at: http://www. aids2006.org/mainpage
14. Lorenzi P, Spicher VM, Laubereau B, et al. Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV study. AIDS 1998;12:241-247
15. Goldstein PJ, Smit R, Stevens M, Sever JL. Association between HIV in pregnancy and antiretroviral therapy, including protease inhibitors and low birth weight infants. Infect Dis Obstet Gynecol 2000;8:94-98
16. Beckerman K, Covington DL, Garcia P, et al. Association between antiretroviral therapy during pregnancy and prematurity/ low birth weight. Oral presentation at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, 2004. Available at: http://www.retroconference. org/AbstractSearch